Results 21 to 30 of about 16,268 (199)

In Vitro and In Vivo Evaluations of β-Lactam/β-Lactamase Mono- and Combined Therapies against Carbapenem-Nonsusceptible Enterobacteriaceae in Taiwan

Microorganisms, 2020
Increasing carbapenem resistance rates worldwide underscored the urgent need of novel antimicrobials. Ceftazidime–avibactam and aztreonam–avibactam combinations are developed to combat carbapenem resistance, but biological and geographic variations must ...
Tsung-Ying Yang, Ya-Ju Hsieh, Li-Ting Kao, Guan-Hong Liu, Shao-Hsuan Lian, Liang-Chun Wang, I-Ling Lin, Yu-Tzu Lin, Sheng-Fan Wang, Sung-Pin Tseng, Po-Liang Lu   +10 more
doaj   +1 more source

Recent Developments to Cope the Antibacterial Resistance via β-Lactamase Inhibition

Molecules, 2022
Antibacterial resistance towards the β-lactam (BL) drugs is now ubiquitous, and there is a major global health concern associated with the emergence of new β-lactamases (BLAs) as the primary cause of resistance.
Zafar Iqbal, Jian Sun, Haikang Yang, Jingwen Ji, Lili He, Lijuan Zhai, Jinbo Ji, Pengjuan Zhou, Dong Tang, Yangxiu Mu, Lin Wang, Zhixiang Yang   +11 more
doaj   +1 more source

NCY-1 β-Lactamase Activity Correlates With Antimicrobial Susceptibility of a Clinical Strain of Nocardia cyriacigeorgica. [PDF]

Microbiologyopen
This study shows a strong correlation between the β‐lactam susceptibility profile of a clinical isolate of Nocardia cyriacigeorgica and the activity of its β‐lactamase, NCY‐1. Inhibitors of NCY‐1 reduce the minimum inhibitory concentration of amoxicillin.
Couston J, Le Marchand A, Hodille E, Genestet C, Joannard B, Feuillard J, Benito Y, Dumitrescu O, Blaise M.   +8 more
europepmc   +2 more sources

Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia [PDF]

, 2020
BACKGROUND: Cefiderocol is a novel siderophore cephalosporin, developed for activity against MDR Gram-negative bacilli (MDR-GNB). OBJECTIVES: To assess the in vitro antibacterial activity of cefiderocol against a collection of MDR-GNB clinical ...
Conejo, Mª del Carmen, Delgado Valverde, María Mercedes, Fernández Cuenca, Felipe Manuel, Pascual Hernández, Álvaro, Serrano, Lara   +4 more
core   +1 more source

Cefdinir and β-Lactamase Inhibitor Independent Efficacy Against Mycobacterium tuberculosis

Frontiers in Pharmacology, 2021
Background: There is renewed interest in repurposing β-lactam antibiotics for treatment of tuberculosis (TB). We investigated efficacy of cefdinir, that withstand the β-lactamase enzyme present in many bacteria, against drug-susceptible and multi-drug ...
Shashikant Srivastava, Shashikant Srivastava, Tania Thomas, Dave Howe, Lesibana Malinga, Prithvi Raj, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Jan-Willem Alffenaar, Tawanda Gumbo, Tawanda Gumbo   +10 more
doaj   +1 more source

Successful Treatment of Acute Prostatitis Caused by Multidrug-Resistant Escherichia coli With Tigecycline Monotherapy [PDF]

, 2020
We present a successful treatment, with tigecycline monotherapy, of acute prostatitis caused by multidrug-resistant Escherichia coli harboring an NDM-1 carbapemenase along with a CMY-2 cephalosporinase and a TEM ...
Babouee Flury, Baharak, Buetti, Niccolo, Casanova, Carlo, Furrer, Hansjakob, Jent, Philipp, Livermore, David M, Lo Priore, Elia, Pelzer, Niklas   +7 more
core   +2 more sources

Synergistic Effect of Clinically Available Beta-Lactamase Inhibitors Combined with Cefiderocol against Carbapenemase-Producing Gram-Negative Organisms

Antibiotics, 2022
The role of β-lactamases in reduced susceptibility or resistance to cefiderocol has been supported by recent reports. The purpose of this study was to investigate the in vitro impact of clinically available β-lactamase inhibitors on cefiderocol activity ...
Gabriele Bianco, Paolo Gaibani, Sara Comini, Matteo Boattini, Giuliana Banche, Cristina Costa, Rossana Cavallo, Patrice Nordmann   +7 more
doaj   +1 more source

Ceftazidime-avibactam

Revista Española de Quimioterapia, 2022
The increase in nosocomial infections by beta-lactamase producing Gram-negative bacilli constitutes a therapeutic challenge. The combination of ceftazidime-avibactam offers a very interesting therapeutic option for nosocomial pneumonia caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae, multidrug-resistant Pseudomonas aeruginosa,
openaire   +2 more sources

European intensive care physicians’ experience of infections due to antibiotic-resistant bacteria [PDF]

, 2020
Background Antimicrobial resistance (AMR) compromises the treatment of patients with serious infections in intensive care units (ICUs), and intensive care physicians are increasingly facing patients with bacterial infections with limited or no adequate ...
De Waele, Jan, Friggeri, Arnaud, Garnacho-Montero, José, Gustin, Marie Paule, Jean, Astrid, Kohlenberg, Anke, Lepape, Alain, Monnet, Dominique L., Savey, Anne, Vanhems, Philippe   +9 more
core   +2 more sources

A New Twist: The Combination of Sulbactam/Avibactam Enhances Sulbactam Activity against Carbapenem-Resistant Acinetobacter baumannii (CRAB) Isolates

Antibiotics, 2021
An increasing number of untreatable infections are recorded every year. Many studies have focused their efforts on developing new β-lactamase inhibitors to treat multi-drug resistant (MDR) isolates. In the present study, sulbactam/avibactam and sulbactam/
Fernando Pasteran, Jose Cedano, Michelle Baez, Ezequiel Albornoz, Melina Rapoport, Jose Osteria, Sabrina Montaña, Casin Le, Grace Ra, Robert A. Bonomo, Marcelo E. Tolmasky, Mark Adams, Alejandra Corso, Maria Soledad Ramirez   +13 more
doaj   +1 more source